Your oncologist is treating the cancer, but who’s tracking the metabolic fire that may be feeding it?
If you or someone you love is fighting cancer, the answer to that question may decide more than the treatment plan itself. Oncologists monitor basic labs to watch for treatment side effects, but there’s a much bigger picture that often goes unseen: the metabolic conditions that can drive cancer progression, blunt treatment response, or set the stage for recurrence after remission. And most patients never receive the critical labs that could change everything. The vast majority of oncologists are simply not ordering them.
Cancer does not exist in a vacuum. It thrives within a metabolic environment that either supports or resists its growth. Insulin resistance, chronic inflammation, oxidative stress, interstitial fluid acidity, hormonal imbalances, and nutritional deficiencies are not background noise. They are the conditions that feed the fire. And most cancer patients have never had them properly tested or interpreted. Think of it like trying to put out a campfire while someone keeps throwing gasoline on it. Until you remove the fuel, the fire will return.
The danger of omitting these labs is not theoretical. When these metabolic drivers go unmeasured, they go unmanaged. And when they go unmanaged, patients in active treatment may be fighting the disease with one hand while their own metabolism fuels it with the other, and patients who believe they are in remission may be walking around in a body that is still metabolically primed for recurrence. Whether the cancer is being actively treated or has been declared gone, the conditions that support its growth remain fully intact and unchallenged if no one is looking for them
Comments from Dr. Thomas: “I recently reviewed labs for a patient whose oncologist had declared her in remission. Her standard bloodwork looked fine. But her fasting insulin was 22 uIU/mL, her hs-CRP was elevated at 4.8 mg/L, her vitamin D was 24 ng/mL, and her neutrophil-to-lymphocyte ratio was 4.1. She was metabolically still feeding the fire, and no one had told her. The right panel of labs finds the presence of pathology to repair, such as an insulin-resistant, hyperinflammatory patient with cancer-promoting biology, and her numbers told exactly that story. Her case is not unusual. It is, in my experience, the norm. Whether your own bloodwork is quietly saying something similar is the most important question you can ask right now.”
Cancer as a Metabolic Disease: The Terrain Before the Tumor
Medicine has long understood that addressing a disease is not the same as addressing the conditions that produced it. The physician who treats the wound but ignores the conditions that produced it has done something, but not everything. The physician who maps the pathogen but not the conditions in which it thrives has answered one question while leaving the larger one unasked. Oncology now finds itself in the same position. Removing or shrinking a tumor is necessary work, but it is incomplete work if the metabolic terrain that allowed the tumor to take root, and that will be present if it returns, remains untouched.
For nearly a century, researchers have recognized that cancer cells handle energy and nutrients differently than healthy cells. The observation dates to the 1920s, when Otto Warburg noticed that cancer cells burn glucose in an unusual way, producing large amounts of lactate even when plenty of oxygen is available. This pattern is so distinctive that it still bears his name today, the Warburg effect. Warburg’s insight was largely pushed aside during the decades when cancer research focused almost exclusively on genetic mutations, but it has come roaring back over the last fifteen years. Cancer has been called a “metabolic disease,” and for good reason. A growing body of work, led most visibly by Thomas Seyfried, PhD, at Boston College, now views cancer fundamentally as a disorder of how cells produce energy and handle nutrients, with genetic mutations serving more as facilitators than as first causes. Struggling mitochondria, disordered nutrient signaling, and the loss of metabolic flexibility do not just come along for the ride during cancer development. They help set the stage for it.
This framing has direct consequences for how we think about the labs described in the rest of this article. Cancer and cardiometabolic diseases often travel along the same highway, driven by the same underlying metabolic problems and branching off at different exits depending on a person’s genetics, tissue vulnerabilities, and lifetime exposures. The same biomarkers that predict cardiovascular disease and type 2 diabetes, including fasting insulin and HOMA-IR, hemoglobin A1c, the triglyceride-to-HDL ratio, high-sensitivity C-reactive protein, fasting glucose, apolipoprotein B, oxidized LDL, the neutrophil-to-lymphocyte ratio, and waist circumference, also help predict cancer risk, mortality, and how likely an existing cancer is to resist treatment. Chronically high insulin acts as a steady growth signal through the IGF-1 axis. Elevated blood sugar preferentially feeds the kind of energy metabolism cancer cells favor. Widespread inflammation, reflected by a high hs-CRP and a rising neutrophil-to-lymphocyte ratio, creates the same pro-cancer environment throughout the body that tumors build around themselves locally. Oxidized LDL reflects ongoing damage to DNA, proteins, and fats, the kind of damage that helps start cancer in the first place and helps it resist treatment once established. Abnormal cholesterol patterns change the supply of fatty acids that cancer cells use for fuel. And visceral fat, the fat stored deep around your organs, behaves like an active hormone-producing organ, releasing inflammatory chemicals and extra estrogens that pour into the same hostile internal environment.
When these biomarkers drift out of their optimal range, the body begins to resemble, in miniature, the conditions that make established tumors so hard to treat. A body marked by insulin resistance, chronic low-grade inflammation, oxidative stress, and struggling mitochondria is a body in which the supportive environment for cancer is already partially built. Cancer cells that arise in this setting do not have to build a hostile neighborhood from scratch. They inherit one. And for patients who already have cancer, those same out-of-range numbers may influence the response to chemotherapy, radiation, and immunotherapy by maintaining inflammatory, insulin-driven, and oxidatively stressed conditions that cancer cells exploit to adapt and survive. Normalizing these biomarkers is therefore not a soft, preventive afterthought. In patients with active disease, it can support the conditions under which the immune system and conventional therapies do their work, in close coordination with the treating oncologist. In patients who have completed treatment and been told they are in remission, it is how the same conditions that supported the original cancer are addressed proactively, so the metabolic environment looks different from the one in which the cancer originally took hold.
The Cell Danger Response: When the Body’s Defense Becomes Cancer’s Foundation
To understand why these labs matter so much, it helps to grasp a concept that has emerged from the work of Robert Naviaux, MD, PhD, at the University of California, San Diego: the cell danger response, or CDR. The CDR is the evolutionarily ancient, metabolically coordinated defense reaction that every cell mounts when it senses a threat, whether that threat is a virus, a toxin, a heavy metal, an infection, chronic psychological stress, a poor diet, or sustained inflammation. When the threat is acute and the body resolves it cleanly, the CDR completes its healing cycle, and the cell returns to normal function. The problem arises when the threats never go away, because then the danger signal never turns off.
At its core, the CDR is a mitochondrial threat-response program. It activates when cells sense that the environment outside them is unsafe. When the CDR is held open by an unrelenting stream of metabolic insults, mitochondria shift away from efficient oxygen-based energy production and toward a defensive posture that resembles what Warburg first described in cancer cells. Glycolysis takes over. Reactive oxygen species pour out. Cell membranes stiffen. The cell stops communicating normally with its neighbors. Inflammatory danger signals, including ATP and mitochondrial DNA fragments, leak into the surrounding tissue, recruiting immune cells that further amplify the inflammatory environment. The clotting system activates. Insulin signaling is distorted. Hormone production shifts. Detoxification slows. A cell stuck in chronic CDR is, in effect, a cell that has never been allowed to finish the work of healing because the threats it was first responding to are still present, and a body in which large numbers of cells are stuck in this state is a body whose internal terrain begins to look exactly like the terrain that established tumors create around themselves.
This is why the CDR matters so deeply in cancer. A chronic CDR may contribute to cancer initiation by sustaining, over years and decades, the mitochondrial dysfunction, oxidative damage, and disordered cellular communication that allow malignant transformation to take hold. And once a tumor is established, that same chronic CDR may help maintain the inflammatory, hypoxic, glycolytic, hypercoagulable, and immunosuppressed environment that cancer cells exploit to grow, invade, and resist treatment. But the CDR does not switch itself on without provocation, and it does not stay on without ongoing input. Something has to keep triggering it. That something is precisely what the lab markers in the rest of this article are designed to reveal.
What keeps the CDR engaged is a particular set of chronic, measurable insults that the cell registers as danger and responds to by holding its defense program open. Chronic hyperinsulinemia and disordered glucose handling deliver a continuous metabolic signal that distorts mitochondrial function and signals to every cell exposed to it that the system is in overload, while the glycation damage and oxidative bursts that accompany unstable blood sugar are registered as direct chemical injury. A sustained inflammatory milieu bathes every cell in danger signals from neighboring tissues. Damaged, oxidized lipid particles act as damage-associated molecular patterns in their own right, particles whose very presence triggers the inflammatory and defensive responses that lock cells into CDR. An accumulated iron burden drives the Fenton reaction, generating the reactive oxygen species the cell experiences as an ongoing chemical assault. Damage to the vascular lining, combined with impaired methylation, leaves cells with fewer tools to quiet their stress responses. A clotting system pulled into a feedforward loop with inflammation deepens the cycle with each turn. Suppressed active thyroid signaling and chronically elevated stress hormones hold metabolism in a stress posture indefinitely. The loss of one of the body’s most important brakes on inflammatory signaling leaves danger signals unchecked when they should be quieted. And acidosis of the interstitial fluid is itself registered by cells as a threat to survival. Taken together, these chronic insults do not simply reflect an unwell body. They are the specific, ongoing inputs that keep the cell danger response switched on, and as long as they persist, the CDR cannot complete its healing cycle.
This reframes the purpose of correcting these markers. Each value brought back into its optimal range is not just a number improved; it is one less danger signal arriving at the cell. As these inputs are reduced one by one, the cumulative threat load drops below the threshold that keeps the CDR engaged, mitochondria are permitted to return to efficient energy production, the healing cycle that has been stuck for years can be completed, and the internal environment may shift from one that supports cancer to one that resists it. That is the deeper reason that targeted, lab-guided support matters, both during active treatment in coordination with the oncology team and after remission has been declared.
Glucose Metabolism Markers
Cancer’s primary fuel source is glucose, and the combined markers of fasting glucose, fasting insulin, HOMA-IR, hemoglobin A1c, and 1,5-anhydroglucitol (GlycoMark) reveal how strongly the body’s glucose regulation may be supporting tumor growth. Insulin resistance is the metabolic fingerprint that the body is in metabolic disarray, and research consistently shows that cancer patients often have insulin resistance on par with type 2 diabetes. In a large Journal of Clinical Oncology analysis, breast cancer patients with fasting insulin in the highest quartile had a 2.1-fold higher risk of recurrence and nearly triple the mortality compared to those in the lowest quartile. Standard glucose tests alone miss early insulin resistance, the very condition that drives so much of the downstream metabolic damage. GlycoMark detects glucose spikes that hemoglobin A1c cannot see, spikes that directly injure blood vessels and amplify oxidative stress. When all five markers are combined, they create the earliest and most actionable picture of glucose metabolism, long before metabolic chaos can be exploited to accelerate cancer growth.
IGF-1
Insulin-like growth factor 1 is one of the most potent growth signals in the body. It tells cells to grow and multiply while suppressing natural cell death, both of which are deeply problematic when cancer cells are present. High animal protein intake elevates IGF-1, and higher levels are consistently linked to increased risk of several cancers, including breast, prostate, and colorectal cancer. Careful interpretation matters here because IGF-1 also plays an important role in maintaining healthy tissues. Too low, and the body loses muscle mass, bone density, and tissue repair capacity. Too high, and the body presses the accelerator on cellular growth in a system that may already be struggling to keep abnormal cells in check. Finding the right balance requires testing, not guessing.
Inflammatory Markers
Chronic inflammation contributes to the environment in which cancer thrives. High-sensitivity C-reactive protein (hs-CRP) and homocysteine measure cancer-relevant inflammation in the body. Elevated hs-CRP is one of the strongest independent predictors of both cardiovascular events and the kind of systemic inflammation associated with tumor growth. In multiple large cohort studies, patients with hs-CRP levels above 3.0 mg/L have been shown to have significantly higher rates of cancer progression and shorter overall survival across several tumor types. Homocysteine signals dysfunction in the methylation pathways critical to DNA repair and detoxification. Addressing elevated inflammation can help create an internal environment less favorable to tumor growth, invasion, and metastasis. The good news is that elevated homocysteine is often correctable with targeted B-vitamin support.
Neutrophil-to-Lymphocyte Ratio
This simple calculation from your complete blood count is one of the most powerful and inexpensive prognostic markers in oncology. A meta-analysis of over 100 studies encompassing more than 40,000 patients found that an elevated NLR was associated with significantly worse overall survival across virtually every solid tumor type. Here is what most patients do not realize: this number is already on standard bloodwork. It just needs to be calculated and interpreted in the context of the specific cancer. The oncologist has this data in hand at every visit. It is simply not being used. An elevated platelet count, meanwhile, can signal chronic inflammatory states associated with both tumor growth and the systemic deterioration that may undermine the body’s ability to respond to treatment.
Lipids: Apolipoprotein B, Oxidized LDL, and Triglyceride-to-HDL Ratio
Standard cholesterol panels report LDL as a concentration, but what actually matters is the number of particles carrying that cholesterol. Apolipoprotein B (ApoB) is the direct measure of that count. Every atherogenic lipoprotein particle carries exactly one ApoB molecule, making ApoB the single most accurate measure of how many potentially harmful particles are in circulation. Two patients with identical LDL cholesterol levels can have dramatically different particle counts, and the patient with more particles carries the greater risk. Elevated ApoB levels are associated with chronic low-grade inflammation, impaired microvascular function, and delivery of lipid building blocks to tumor cells, which upregulate their LDL receptors during rapid growth. But quantity is only half the story.
Oxidized LDL tells you how many of those particles have been damaged by oxidative stress. Once oxidized, these particles activate inflammatory signaling in tissue macrophages, degrade the protective lining of capillaries, and damage cellular DNA throughout the body, thereby contributing to the accumulation of mutations that initiate cancer and to the development of treatment resistance in existing cancers.
The triglyceride-to-HDL ratio adds a third dimension to this picture. A high ratio basically means there is too much fat circulating in the blood and not enough HDL, the “protective” cholesterol that helps clean up inflammation and oxidative damage, and this combination is associated with a metabolic environment more permissive to cancer growth. When triglycerides are high, the body is usually dealing with insulin resistance, higher estrogen activity, and more inflammatory signals, all of which can push cells toward abnormal growth. When HDL is low, the body loses a major antioxidant and anti-inflammatory defense system that normally helps protect DNA from damage. Together, a high TG/HDL ratio reflects chronic inflammation, oxidative stress, hormonal imbalance, and poor metabolic health, and studies link this pattern to an increased risk of several cancers. In simple terms, the higher the triglycerides and the lower the HDL, the more fertile the internal environment may become for cancer to develop or progress.
Together, ApoB, oxidized LDL, and the TG/HDL ratio reveal whether the cholesterol in the blood is not only excessive in quantity but actively damaging cellular machinery and sitting inside a metabolic pattern associated with cancer growth, a combination that standard lipid panels miss entirely.
Iron and Copper
Elevated ferritin (iron) and ceruloplasmin (copper) are associated with a pro-cancer environment. Cancer cells have an increased demand for iron, and excess iron is a potent pro-oxidant that generates free radicals through the Fenton reaction, directly damaging DNA and cellular structures. In practical terms, this means that if ferritin is chronically elevated, the body is generating ongoing oxidative damage that may contribute to the mutations and cellular instability associated with cancer progression. Copper plays a critical role in angiogenesis, the formation of new blood vessels that tumors need to grow and spread. Without an adequate blood supply, a tumor cannot grow beyond the size of a pinhead. Elevated copper supports the infrastructure tumors require. Both deficiency and excess are harmful. Iron deficiency impairs oxygen delivery and exercise capacity. Iron overload contributes to oxidative damage of cellular structures. Only testing reveals where a patient stands, and only optimal-range interpretation suggests what to do about it.
Coagulation Markers
Elevated D-dimer and fibrinogen activity are associated with cancer progression and treatment resistance. Cancer creates a hypercoagulable state that may facilitate metastasis. Most doctors order coagulation tests only when a patient presents with a clotting event, but chronically elevated levels in otherwise stable patients are powerful predictors of future cardiovascular events, stroke, and cancer-related outcomes. What many patients do not realize is that the coagulation system is not a passive bystander in cancer. Many tumors actively exploit it. Fibrin deposits can physically shield circulating tumor cells from immune detection, and elevated D-dimer levels have been independently associated with shorter survival in patients with advanced cancers. These markers reveal whether the clotting system is being recruited by the disease.
Thyroid and Cortisol
Low thyroid function and chronically elevated cortisol are two overlooked metabolic factors that can quietly shape the internal terrain in cancer’s favor. Low thyroid levels slow cellular metabolism, weaken immune surveillance, and increase systemic inflammation, the same inflammatory environment associated with tumor growth. This is why assessing thyroid status with a Free T3-to-Reverse T3 ratio, rather than relying on TSH alone, is so important. The ratio reflects how much active thyroid hormone cells actually receive and gives a far better picture of whether the metabolic engine is running efficiently or stuck in low gear. Excess cortisol adds another layer of metabolic stress by suppressing immune activity, raising blood sugar and insulin, and increasing oxidative damage, which amplifies the very conditions, such as insulin resistance, inflammation, oxidative stress, and acidic interstitial chemistry, that cancer cells exploit to grow, invade, and resist treatment. Together, low thyroid and high cortisol do not cause cancer by themselves, but they create a biological landscape in which cancer may spread more easily, and conventional therapies may have to work harder to succeed.
Vitamins B12 and D
High vitamin B12 levels from excess supplementation can push the body into a state where cell growth signals become louder than they should be, and certain cancers are very good at taking advantage of that extra fuel. When B12 is far above normal, it can overstimulate methylation pathways, which are the chemical switches that help control which genes stay quiet and which genes stay active, and this can accidentally strengthen growth programs that cancer cells already rely on. Very high B12 can also raise the proteins that carry B12 through the bloodstream, and these proteins are often elevated in people with active tumors because cancer cells use them to support rapid division. The overall effect is not that B12 creates cancer out of nowhere, but that unusually high levels may make it easier for an existing or developing cancer to grow, survive, and spread by giving it more of the raw materials it prefers.
Low vitamin D is associated with worse cancer outcomes across multiple cancer types. This is one of the most correctable deficiencies in medicine, yet it is often not monitored during cancer treatment. Vitamin D functions as a hormone that influences immune regulation, cardiovascular protection, and cancer-related biology. Vitamin D receptors are present throughout the body, and optimal levels support the immune surveillance systems that recognize and eliminate abnormal cells. The “normal” range for vitamin D extends down to 30 ng/mL, a level at which immune impairment and poor outcomes are already well documented. A pooled analysis of prospective studies found that patients with vitamin D levels below 20 ng/mL had a 30-50% higher cancer-specific mortality compared to those with levels above 40 ng/mL. Optimal is not the same as normal.
Urine pH
Urine pH tends to mirror the pH of the interstitium, the body-wide fluid-filled network that surrounds every cell, every tissue, and every tumor. Because the kidneys continuously filter and sample this interstitial fluid, they adjust urine chemistry in direct response to the acid-base conditions they detect there.
The interstitium is now understood to be its own fluid circulatory system, larger than the bloodstream and the lymphatic system combined. It is a mechanically pumped, collagen-supported network that moves interstitial fluid throughout the body and drains into lymphatics. This fluid is the immediate environment in which all cells, including cancer cells, live and respond to metabolic stress. An acidic interstitium reflects an acidic tumor microenvironment that can suppress immune activity, promote invasion and metastasis, increase treatment resistance, and support cancer stem cell survival.
Consistently acidic urine (pH below 7) suggests an interstitium under metabolic strain driven by diet, inflammation, hypoxia, lactate production, and impaired buffering. In contrast, research associates a urine pH in the 7.5-8.0 range with a more alkaline interstitial environment that supports mitochondrial efficiency, immune competence, and a terrain less permissive to tumor progression.
Why Optimal Ranges and Expert Interpretation Matter
Perhaps the most important distinction in all of this is the difference between “normal” and “optimal.” Standard reference ranges are derived from population averages that include large numbers of people who are already metabolically unhealthy. Falling within the “normal” range often means only that you are no sicker than the average American, a bar that is disturbingly low. Optimal ranges are based on published research and clinical experience that identifies the levels associated with the lowest disease risk and the best functional outcomes. A fasting insulin level of 20 uIU/mL is technically “normal” by most lab standards, but it reflects a degree of insulin resistance that substantially contributes to the metabolic environment in which cancer thrives.
But choosing the right reference range is only the first layer of interpretation. The second, and harder one, is reading each number in the context of the others. The same fasting insulin of 18 uIU/mL means something different in a patient whose IGF-1 is 240 ng/mL than in a patient whose IGF-1 is 95 ng/mL. The same ferritin level of 280 ng/mL means something different in a patient with elevated hs-CRP than in a patient with quiet inflammation. The same elevated neutrophil-to-lymphocyte ratio carries different implications in a patient mid-chemotherapy than in a patient three years out from treatment. Numbers do not interpret themselves, and the same number on two different patients can point to two different conversations with the treating medical team.
This is the gap that catches most patients who try to navigate metabolic optimization on their own or through practitioners unfamiliar with cancer biology. Direct-to-consumer lab services can deliver the panel, but they cannot tell you which findings to discuss first with your medical team, which to address simultaneously, or which to leave alone, because correcting them too aggressively can worsen something else. Functional medicine has built important frameworks for metabolic health in general, but cancer-specific metabolic medicine is not the same discipline. The interactions between insulin signaling and the IGF-1 axis, between iron metabolism and the Fenton reaction in a tumor-bearing host, between interstitial acidity and treatment response, and between cortisol and the immune surveillance systems that recognize abnormal cells are not standard functional-medicine territory. They are the territory where this work has to be done.
Practically, this means that the labs themselves are necessary but not sufficient. Without the right interpretive lens, a panel of cancer-relevant biomarkers can leave a patient with more data than direction, more options than priorities, and more confidence in the wrong corrections than in the right ones. With the right lens, those same numbers become direction for productive conversations with the oncology team.
Where This Leaves You
If you have read this far, you already understand something that most cancer patients never learn: the standard oncology panel is not enough. The metabolic conditions associated with cancer progression, treatment response, and recurrence are measurable and, in most cases, modifiable. But they can only be modified if someone is looking for them.
Ask your oncologist if these markers can be added to your next blood draw. Some will be willing, and that is a great place to start. But in my experience, most oncologists are focused on tumor-directed treatment and are either unfamiliar with these markers, unable to order them within their system, or unsure how to interpret them in the context of cancer biology. If that describes your situation, you are not alone, and you do not have to wait.
What Progress Looks Like
What patients consistently describe once these metabolic markers begin moving into their optimal ranges is not a single dramatic moment but a quiet return of things they had forgotten were missing. Energy returns first in small increments, then in ways that family members often notice before the patient does. The low-grade inflammation eases, and with it the aches, the mental fog, and the persistent sense that the body is working against itself. Sleep deepens. Body composition shifts in the direction it is supposed to shift. Fasting insulin drops. Hs-CRP falls. The neutrophil-to-lymphocyte ratio comes down. Vitamin D climbs into the range where immune surveillance actually works. These changes rarely happen all at once, but when tracked over 3-6 months of targeted support, the trajectory becomes recognizable. Perhaps the most meaningful change, though, is not a number on a lab report. It is the shift in how patients experience their own care. They stop feeling like passengers in a process being done to them and start feeling like active participants in a plan they understand and can discuss with their treating team. That shift, from passive recipient to informed participant, is often as valuable as any single element of the protocol.
Address the Conditions That Support Cancer Growth: Take the Next Step Today
Every day these metabolic imbalances go undetected is another day the body’s internal environment may be working in favor of conditions associated with cancer growth rather than against them. And the question of timing is not abstract. For patients in active treatment, every cycle of chemotherapy, radiation, or immunotherapy that proceeds in an unoptimized metabolic environment is a cycle in which those therapies may be working in a context that could be improved. The same inflammatory, insulin-driven, oxidatively stressed conditions that contribute to treatment resistance in laboratory studies do not pause during an infusion schedule. They continue in real time, and waiting six months to address them means six months of treatment delivered into a body whose metabolic environment has not been optimized.
For patients who have completed treatment and been told they are in remission, the urgency is different but no less real. The highest-risk window for recurrence in many solid tumors falls within the first 2-3 years after treatment ends, though for some hormone-driven cancers the risk extends considerably longer. That window, whatever its duration for a particular disease, is when the metabolic conditions that supported the original cancer are either addressed or quietly remain in place. In both cases, the cost of waiting is not measured in inconvenience. It is measured in biology that continues to move in the wrong direction while no one is looking.
What makes this approach distinctive is that the protocol is not a template. It is built directly from what the specific bloodwork reveals. Two patients with the same diagnosis can have very different metabolic drivers, and therefore very different paths back to an internal environment less permissive to cancer growth. One patient’s labs may indicate insulin resistance and elevated IGF-1 as the dominant factors. Another’s may reveal that oxidative stress, an acidic interstitial terrain, and low vitamin D are the most prominent issues. A third may be clotting abnormally, while a sluggish thyroid quietly suppresses immune surveillance in the background. These are not the same problem, and they do not respond to the same approaches. The bloodwork is the blueprint. Without it, every recommendation is a guess. With it, every recommendation, whether dietary, supplemental, lifestyle, or for discussion with the medical team, is targeted to the specific metabolic factors at work in a specific body, not a generic body.
Dr. Thomas offers a structured consultation designed to address the metabolic picture that standard oncology often leaves unexamined. It includes a comprehensive lab order covering the cancer-relevant biomarkers described above, a two-hour strategic session to transform the data into a personalized written analysis, and a detailed written report covering dietary strategies, targeted supplementation, lifestyle modifications, and additional options to discuss with your medical team.
One component of the consultation that patients consistently say is worth the cost on its own is the supplement review. Most cancer patients are taking multiple supplements, often based on internet research, well-meaning advice from friends, or recommendations from practitioners unfamiliar with their treatment regimen. In the review, Dr. Thomas identifies which supplements are likely supporting the patient’s goals, which appear to be doing nothing, and which may warrant discussion with the oncology team regarding potential interactions. For many patients, what they stop taking matters as much as what they start.
Appointments are available in-office or via telemedicine. The consultation fee is $1,500. The full two-hour session is unhurried by design, deep enough to work through the specific labs systematically, weigh the interactions between findings, and answer the questions that standard oncology visits rarely have time to address. The time itself, however, is only part of what patients are paying for. They are paying for Dr. Thomas’s experience, expertise, and judgment regarding which numbers matter in their specific case, which considerations are worth pursuing with their medical team, and which are not. Patients consider it one of the best investments they have made in their cancer journey.
Personal guarantee from Dr. Thomas: “I want to make this decision as straightforward as possible. If, during our two-hour strategic session, I do not identify at least three actionable metabolic drivers worth addressing in your case, your consultation fee will be refunded in full. After 40 years of practice, I have reviewed thousands of these panels on patients in active treatment and in remission. I have yet to review a set on a cancer patient and not find meaningful targets for intervention. I do not want the fee to stand between a patient and the information that could change the course of their care.”
Do not leave your metabolic health to chance. Download and complete our one-page Prospective Patient Form and email it to info@healthyandstrong.com or fax it to 888-481-6799. You can also call us at 352-729-0923. The sooner you uncover what may be feeding the fire, the sooner you can start putting it out.
Dr. Daniel Thomas, DO, MS
2110 N. Donnelly St., Suite 109
Mount Dora, FL 32757
Phone: 352-729-0923
Fax: 888-481-6799
Email: info@healthyandstrong.com
